HomeClinical TopicsFDA targets companies selling unapproved products for treating opioid addiction

FDA targets companies selling unapproved products for treating opioid addiction

Author(s):

On Jan. 24, the U.S. Food and Drug Administration (FDA) announced that along with the Federal Trade Commission it posted joint warning letters to the marketers and distributors of 12 opioid cessation products, for illegally marketing unapproved products with claims about their ability to help in the treatment of opioid addiction and withdrawal.

Read more via Fda.gov.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Recent Content